marked.bio

c-MET ADC · ADC

telisotuzumab vedotin

2 active trials, targeting c-MET. Not approved for any biomarker on marked.bio yet.

Also known as ABBV-399, Teliso-V, Emrelis.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 2 3 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of telisotuzumab vedotin.

  1. AbbVie 1

Trials

2 of 3 trials shown

  1. Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

    Recruiting Phase 2 Jonsson Comprehensive Cancer Center Started 2026Primary completion 2027-02 NCT07323641

    osimertinib FDA EUtelisotuzumab vedotin

    Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to osimertinib.

    EGFR exon 19 deletion / L858RLung Non-Small Cell Carcinoma

  2. A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

    Active, not recruiting Phase 1 AbbVie Started 2014Primary completion 2026-08 NCT02099058

    osimertinib FDA EUnivolumabtelisotuzumab vedotinerlotinib FDA EU

    …ced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resi…

    EGFR exon 19 deletion / L858RAdvanced Solid Tumors Cancer